文献速递糖尿病

2型糖尿病中磺脲类药物作为二线药物的心血管安全性:一项全国性人群比较安全性研究

Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study.
PubMed 文献 · Diabetes Care · 2023-01-01

该研究基于苏格兰全国人群队列,纳入二甲双胍单药治疗未达HbA1c 48 mmol/mol且于2010年1月1日或之后启动二线药物(磺脲类/DPP4i/TZD)的2型糖尿病患者,比较磺脲类与非磺脲类(DPP4i/TZD)的心血管安全性。多变量Cox回归和工具变量分析显示,磺脲类与MACE风险(HR 1.00,95%CI 0.91-1.09)及全因死亡风险(HR 1.03,95%CI 0.94-1.13)无显著差异。结论认为二线磺脲类降糖不太可能增加心血管风险或全因死亡率,支持磺脲类继续作为全球糖尿病治疗组合的一部分。

要点

  • 磺脲类与非磺脲类(DPP4i/TZD)相比,MACE的HR为1.00(95%CI 0.91-1.09),无显著差异。
  • 全因死亡的HR为1.03(95%CI 0.94-1.13),无显著差异。
  • 结论认为二线磺脲类降糖不太可能增加心血管风险或全因死亡率。

核心结论

  • 研究结果表明,二线磺脲类降糖不太可能增加心血管风险或全因死亡率。
  • 鉴于其强效、微血管获益、成本效益和广泛使用,本研究支持磺脲类应继续作为全球糖尿病治疗组合的一部分。

研究设计与样本

  • 研究为队列研究,纳入苏格兰在2017年12月31日之前诊断为2型糖尿病、尽管二甲双胍单药治疗仍未达到HbA1c 48 mmol/mol、并于2010年1月1日或之后启动二线药物治疗(磺脲类/DPP4i/TZD)的患者。
  • 主要结局为复合主要不良心血管事件(MACE),包括因心肌梗死、缺血性卒中、心力衰竭住院和心血管死亡。
  • 次要结局为各单项终点和全因死亡。
  • 采用多变量Cox比例风险回归和工具变量(IV)方法控制混杂。

主要发现

  • 磺脲类与非磺脲类(DPP4i/TZD)相比,MACE的多变量Cox回归HR为1.00(95%CI 0.91-1.09),两种不同工具变量分析的HR分别为1.02(95%CI 0.91-1.13)和1.03(95%CI 0.91-1.16)。
  • 全因死亡的多变量Cox回归HR为1.03(95%CI 0.94-1.13),两种工具变量分析的HR分别为1.04(95%CI 0.93-1.17)和1.03(95%CI 0.90-1.17)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the real-world cardiovascular (CV) safety for sulfonylureas (SU), in comparison with dipeptidyl peptidase 4 inhibitors (DPP4i) and thiazolidinediones (TZD), through development of robust methodology for causal inference in a whole nation study. RESEARCH DESIGN AND METHODS: A cohort study was performed including people with type 2 diabetes diagnosed in Scotland before 31 December 2017, who failed to reach HbA1c 48 mmol/mol despite metformin monotherapy and initiated second-line pharmacotherapy (SU/DPP4i/TZD) on or after 1 January 2010. The primary outcome was composite major adverse cardiovascular events (MACE), including hospitalization for myocardial infarction, ischemic stroke, heart failure, and CV death. Secondary outcomes were each individual end point and all-cause death. Multivariable Cox proportional hazards regression and an instrumental variable (IV) approach were used to control confounding in a similar way to the randomization process in a randomized control trial. RESULTS: Comparing SU to non-SU (DPP4i/TZD), the hazard ratio (HR) for MACE was 1.00 (95% CI: 0.91-1.09) from the multivariable Cox regression and 1.02 (0.91-1.13) and 1.03 (0.91-1.16) using two different IVs. For all-cause death, the HR from Cox regression and the two IV analyses was 1.03 (0.94-1.13), 1.04 (0.93-1.17), and 1.03 (0.90-1.17). CONCLUSIONS: Our findings contribute to the understanding that second-line SU for glucose lowering are unlikely to increase CV risk or all-cause mortality. Given their potent efficacy, microvascular benefits, cost effectiveness, and widespread use, this study supports that SU should remain a part of the global diabetes treatment portfolio.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Wang H, Cordiner RLM, Huang Y, et al. Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. Diabetes Care. 2023. PMID: 36944118. doi:10.2337/dc22-1238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。